
5th y Med student | Clinical research | Biostatistics | Cardiology | Electrophysiology | #EPeeps | Medical content creator
مصر
Joined March 2023
- Tweets758
- Following3.2K
- Followers420
- Likes870
Pinned Tweet
Cardiology moves quickly. Clarity should keep pace.
I’m excited to launch CardioCircle—a platform focused on translating trials, guidelines, and evolving evidence into clinically meaningful insights.
This is only the beginning.
Follow CardioCircle and join the circle.
Cardiology has no shortage of information. It has a shortage of clarity.
That is why we built CardioCircle.
CardioCircle examines trials, guidelines, imaging, and clinical controversies through one sharper question:
What does this mean in practice?
Follow CardioCircle. See the evidence. Join the circle.
#CardioCircle #Cardiology #CardioEd #EvidenceBasedMedicine #ClinicalPractice
🚨𝗪𝗼𝘂𝗹𝗱 𝘆𝗼𝘂 𝗲𝗱𝗶𝘁 𝗮 𝗴𝗲𝗻𝗲 𝘁𝗼 𝗹𝗼𝘄𝗲𝗿 𝘁𝗿𝗶𝗴𝗹𝘆𝗰𝗲𝗿𝗶𝗱𝗲𝘀?
🚨𝗪𝗼𝘂𝗹𝗱 𝘆𝗼𝘂 𝗲𝗱𝗶𝘁 𝗮 𝗴𝗲𝗻𝗲 𝘁𝗼 𝗹𝗼𝘄𝗲𝗿 𝘁𝗿𝗶𝗴𝗹𝘆𝗰𝗲𝗿𝗶𝗱𝗲𝘀?
CTX310: one infusion targeting #ANGPTL3; mean triglycerides down 63% at 30 days in ten adults with severe hypertriglyceridemia.
The promise is lasting lipid control. The evidence is an uncontrolled phase 1b cohort.
Long-term safety and prevention of pancreatitis or cardiovascular events remain unproven.
These early findings deserve attention and larger, longer studies.
What evidence would you require before considering gene editing in routine lipid care?
@CRISPRTX @AHAScience
#CardioCircle #CardioX #CardioTwitter #Cardiology #medX #GeneEditing
29
For someone facing years of pacing, preserving ventricular function deserves a place in the first implant decision. OptimPacing compared left bundle branch pacing with right ventricular pacing in adults with atrioventricular block. 👇
🚨𝗪𝗵𝗲𝗿𝗲 𝘄𝗲 𝗽𝗮𝗰𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀.
➡️OptimPacing strengthens the case for protecting ventricular function from the first implant.
🟢 With left bundle branch versus right ventricular pacing, the composite of death, heart failure hospitalization, or pacing-induced cardiomyopathy occurred in 16/342 (4.7%) versus 35/343 (10.2%) over a median of 35 months.
🟢The hazard was 59% lower, but early stopping warrants caution. A composite benefit does not establish a survival benefit.
💬Reliable pacing is the starting point. How we deliver it deserves attention.
@AHAScience @NEJM
#CardioCircle #CardioX #CardioTwitter #EPeeps #ScientificSessions26 #CSP #RVP #LBBP #LBBAP
42
🚨𝗧𝗵𝗲 𝗔𝗜 𝗱𝗶𝘃𝗶𝗱𝗲𝗻𝗱 𝗺𝗮𝘆 𝗯𝗲 𝘁𝗶𝗺𝗲.👇
🚨𝗧𝗵𝗲 𝗔𝗜 𝗱𝗶𝘃𝗶𝗱𝗲𝗻𝗱 𝗺𝗮𝘆 𝗯𝗲 𝘁𝗶𝗺𝗲.
🟢At #ScientificSessions26, AI drafts cut cardiologists’ echo interpretation time from 8.5 to 4.6 minutes.
🟢Substantial edits were needed in 50.6% of AI drafts versus 49.7% of human drafts. Cardiologists finalized every report.
🟢These are preliminary workflow findings; improved patient outcomes were not assessed.
➡️The next test: whether time saved reaches patients through faster reporting and better access.
@HeartNews
#CardioCircle #CardioX #Cardiology #CardioTwitter #MedTech #medicaldevices #Digitalhealth #AIinHealthcare
23
🔴𝗦𝘁𝗼𝗽 𝗼𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲? 𝗠𝗮𝗸𝗲 𝘁𝗵𝗲 𝗰𝗵𝗼𝗶𝗰𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗲𝗱.
🔴𝗦𝘁𝗼𝗽 𝗼𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲? 𝗠𝗮𝗸𝗲 𝘁𝗵𝗲 𝗰𝗵𝗼𝗶𝗰𝗲 𝗶𝗻𝗳𝗼𝗿𝗺𝗲𝗱.
SAGA/SITE and STREAM studied statin discontinuation in older adults without established cardiovascular disease.
Both met non-inferiority criteria, using different outcomes and follow-up. STREAM recorded more composite events after stopping.
Here are the absolute numbers, comparing 𝗦𝗧𝗢𝗣 versus 𝗖𝗢𝗡𝗧𝗜𝗡𝗨𝗘:
🟢𝗦𝗔𝗚𝗔/𝗦𝗜𝗧𝗘 ➡️ all-cause deaths at three years, among participants with available mortality data:
• 35/484 (7.2%) versus 48/604 (7.9%).
🟢𝗦𝗧𝗥𝗘𝗔𝗠 ➡️ nonfatal heart attack, nonfatal ischemic stroke or death:
• First two years: 100/938 (10.7%) versus 77/942 (8.2%).
• Full observed follow-up, extending up to four years: 119/938 (12.7%) versus 87/942 (9.2%).
These are different endpoints and time windows; the percentages should be compared within each trial.
Stopping reduces pill burden, but neither trial demonstrated better quality of life after discontinuation.
Patients should understand the possible loss of cardiovascular protection, alongside uncertainty about their individual benefit.
Discuss absolute risks, tolerability, life expectancy and what matters to them. Then decide together.
@AHAScience
#CardioCircle #CardioX #Cardiology #Statins #STREAM #AHA2026
1
38
STREAM makes a noninferiority claim that its own data undercut: Stopping statins increased heart attacks and strokes, yet the trial was called “noninferior”. Prof #JamesStein18 had not planned to comment on the @AHAScience Sessions this year. But then he read STREAM, an open-label noninferiority trial built on assumptions he finds hard to justify, and he could not let it pass. Its conclusion already is being generalized beyond what the data support. We really need to do better. jamesstein18.substack.com/p/…
How much weight should symptoms and cardiac damage carry before the valve becomes “severe”❓
🚨Moderate stenosis does not always mean low stakes.
#PROGRESS challenges the timing of TAVR: among 744 patients with moderate aortic stenosis and at-risk features, earlier intervention ⬇️reduced the combined endpoint of death or heart failure events at two years.
🟢The benefit came from fewer heart failure events; a survival advantage was not demonstrated.
Patient selection becomes the central issue.
How much weight should symptoms and cardiac damage carry before the valve becomes “severe”❓
@NEJM @EdwardsLifesci @crfheart
nejm.org/doi/full/10.1056/NE…
#CardioCircle #CardioX #CardioTwitter #TCT2026 #TAVR
30
Elsayed Balbaa retweeted
Open Evidence is free for medical students and is now launching a Qbank and flashcards, all supported by their AI.
Introducing Learn, a free, personalized medical education platform from OpenEvidence, built to support trainees and clinicians across their entire careers.
As AI changes how doctors work, it matters just as much that it strengthens how they learn.
Clinicians have made OpenEvidence an everyday tool at the point of care. Now we apply that same technology and those same principles to how doctors learn medicine. Developed with leading medical institutions, certifiers, and educators, Learn brings together a suite of tools built on OpenEvidence so every trainee and clinician gets a tailored, evidence-based learning experience.
P4: CT-guided PCI has been tested in an RCT. 👇
Where should the stent land⁉️ In P4, planning started on coronary CT.
CT-guided PCI was noninferior to IVUS-guided PCI for 1-year target-vessel failure (4.1% vs 4.6%). Median PCI time was 46 vs 63 min.
@ColletCarlos @NEJM @crfheart #TCT2026 #CardioCircle #CardioX #CardioTwitter #CCTA
doi.org/10.1056/NEJMoa261077…
1
50
Next question: Will CCTA-guided PCI reduce long-term mortality and MACE?
Presented at #TCT2026:
In a randomized trial, CCTA-guided PCI with structured preprocedural planning and intraprocedural guidance was noninferior to intravascular ultrasound–guided PCI with respect to target-vessel failure at 12 months. Full P4 trial results: nej.md/48jfVly
@crfheart

ALT A graph from the Original Article "Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI." The trial name, P4, is in parentheses after the title. The graph shows the cumulative incidence of target-vessel failure (primary end point), defined as a composite of death from cardiac causes, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization, at 12 months. The trial results are being presented at the Transcatheter Cardiovascular Therapeutics 2026 Conference. The logo of the New England Journal of Medicine is at the bottom.
51
Closing a heart valve leak without another open-heart operation.
🚨Valve care cannot stop at a successful implant.
Closing a heart valve leak without another open-heart operation.
Paraclose’s value lies in what it may spare suitable patients: another open-heart operation.
@AbbottNews announced FDA approval for Paraclose, a catheter-delivered plug for leaks around surgical replacement valves.
How we manage the next intervention belongs in our definition of success.
#CardioCircle #CardioX #CardioTwitter #StructuralHeart #MedTech
55
𝗧𝗖𝗧 𝟮𝟬𝟮𝟲: 𝟭𝟮 𝘁𝗿𝗶𝗮𝗹𝘀 𝘁𝗼 𝘄𝗮𝘁𝗰𝗵.
𝗧𝗖𝗧 𝟮𝟬𝟮𝟲: 𝟭𝟮 𝘁𝗿𝗶𝗮𝗹𝘀 𝘁𝗼 𝘄𝗮𝘁𝗰𝗵.
Coronary imaging, valve intervention, antithrombotic therapy, and renal denervation are all on our radar.
📍 San Diego | 31 October–3 November
From Cardiovascular Research Foundation’s program (@crfheart), here’s CardioCircle’s watchlist:
𝗦𝗨𝗡𝗗𝗔𝗬 • 𝟭 𝗡𝗢𝗩𝗘𝗠𝗕𝗘𝗥
🔹 P4 ➡️ Coronary CT versus IVUS to guide PCI. @ColletCarlos
🔹 TRANSFORM II ➡️ Sirolimus-coated balloons challenge everolimus-eluting stents. @BernardoCortese @conceptmedicals
🔹 HD-PCI ➡️ Finding the right heparin dose during PCI.
🔹 REMEDY-PILOT ➡️ A sham-controlled test of a coronary sinus reducer for refractory angina without obstructive coronary disease. @JNJMedTech @ShockwaveIVL
🔹 TRAVEL III ➡️ LuX-Valve Plus replacement versus medical therapy for severe tricuspid regurgitation.
𝗠𝗢𝗡𝗗𝗔𝗬 • 𝟮 𝗡𝗢𝗩𝗘𝗠𝗕𝗘𝗥
🔹 PROGRESS ➡️ Earlier TAVR for selected patients with moderate aortic stenosis. @PhilGenereuxMD
🔹 CLASP II TR ➡️ What #PASCAL repair adds to medical therapy for severe, symptomatic tricuspid regurgitation. @EdwardsLifesci
🔹 SIMPLAAFY ➡️ Simplifying antithrombotic treatment after left atrial appendage closure. @bostonsci
𝗧𝗨𝗘𝗦𝗗𝗔𝗬 • 𝟯 𝗡𝗢𝗩𝗘𝗠𝗕𝗘𝗥
🔹 PIONEER IV ➡️ Using angiography-derived coronary physiology to guide PCI.
🔹 EPIC17-VERONICA ➡️ Platelet testing to guide antiplatelet de-escalation after acute coronary syndromes.
🔹 SPYRAL AFFIRM ➡️ US post-approval evidence for radiofrequency renal denervation. @Medtronic @Kandzari
🔹 PROTEMBO IDE ➡️ Testing cerebral embolic protection during TAVR. #protembis
These upcoming presentations could inform patient selection, procedural choices, and the balance between benefit and harm.
Which trial is highest on your watchlist, @TCTMD⁉️
@PCRonline @TCTConference @HeartFlow @Cleerly @ElucidBio @SiemensHealthES
#CardioCircle #TCT2026 #CardioX #InterventionalCardiology #StructuralHeart #TAVR #PCI #DrugCoatedBalloons #LAAO #RenalDenervation #ClinicalTrials #MedTech #Cardiology #P4 #CTguidedPCI #CCTA #ANOCA
67
𝗧𝗵𝗲 𝘀𝘁𝗲𝘁𝗵𝗼𝘀𝗰𝗼𝗽𝗲 𝗴𝗲𝘁𝘀 𝗮𝗻 𝗔𝗜 𝘂𝗽𝗴𝗿𝗮𝗱𝗲.
𝗧𝗵𝗲 𝘀𝘁𝗲𝘁𝗵𝗼𝘀𝗰𝗼𝗽𝗲 𝗴𝗲𝘁𝘀 𝗮𝗻 𝗔𝗜 𝘂𝗽𝗴𝗿𝗮𝗱𝗲.
@Eko_Health’s #FDA-cleared CORE 300 combines analog listening with up to 35× digital amplification, noise cancellation, and a heart-rate display.
Connect it to the Eko App with Eko+ membership for AI-supported structural murmur detection.
Our take: fitting AI into a familiar bedside tool could make adoption easier. Its clinical value will depend on how those findings guide further evaluation and care.
Would you add AI to your stethoscope⁉️
#CardioCircle #CardioX #CardioTwitter #MedTech #medicaldevices #Digitalhealth #AIinHealthcare
67
Elsayed Balbaa retweeted
The best drugs for neuroplasticity?
- regular exercise
- consistent sleep schedule
- diet free of ultraprocessed foods
- daily sunlight
𝗧𝘄𝗼 𝗹𝗲𝗮𝗱𝘀. 𝗔𝘁𝗿𝗶𝗮𝗹 𝘀𝗲𝗻𝘀𝗶𝗻𝗴. 𝗥𝗲𝘀𝘆𝗻𝗰𝗵𝗿𝗼𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻. 👇
𝗧𝘄𝗼 𝗹𝗲𝗮𝗱𝘀. 𝗔𝘁𝗿𝗶𝗮𝗹 𝘀𝗲𝗻𝘀𝗶𝗻𝗴. 𝗥𝗲𝘀𝘆𝗻𝗰𝗵𝗿𝗼𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻.
#BIOTRONIK announced the first US Acticor Sky CRT-DX implant, performed by Dr. Niraj Varma at @ClevelandClinic.
DX technology enables atrial sensing within a two-lead CRT-D system. The platform also includes HeartInsight alerts for worsening heart failure.
The practical attraction: less implanted hardware while retaining atrial information in appropriately selected patients.
A first implant marks adoption; comparative clinical value requires evidence.
Which patients would you consider the best candidates for this approach in your practice⁉️
@BIOTRONIK_News
#CardioCircle #CardioX #CardioTwitter #EPeeps #HeartFailure #MedTech
1
48
𝗔 𝗻𝗮𝘀𝗮𝗹 𝘀𝗽𝗿𝗮𝘆 𝗳𝗼𝗿 𝗔𝗙 𝗿𝗮𝘁𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹?
𝗔 𝗻𝗮𝘀𝗮𝗹 𝘀𝗽𝗿𝗮𝘆 𝗳𝗼𝗿 𝗔𝗙 𝗿𝗮𝘁𝗲 𝗰𝗼𝗻𝘁𝗿𝗼𝗹?
🚨Milestone’s ReVeRA-301 Phase 3 trial has expanded into Europe.
It tests self-administered #etripamil for symptomatic AF with rapid ventricular rate, measuring rate reduction within 30 minutes and symptom improvement.
CARDAMYST is #FDA-approved for acute symptomatic PSVT in adults. AF use remains investigational.
🟢The question is compelling: could selected patients eventually manage these episodes outside hospital under a prescribed treatment plan⁉️
Phase 3 results must establish the benefit and safety of this approach.
@MIST_Milestone
#CardioCircle #CardioTwitter #CardioX #medX #AFib
1
110
Elsayed Balbaa retweeted
Loneliness may cost years of healthy life, not just happiness.
A new study followed nearly 300,000 adults for about 14 years. At baseline none had type 2 #diabetes, heart disease, chronic #respiratory disease, dementia or Parkinson’s, cancer, #anxiety or depression.
Loneliness and social #isolation were both linked to fewer years free of all seven conditions.
At age 50, women who were both hashtag#lonely and isolated had about 2.5 fewer years without physical chronic disease, and men about 2 fewer. The gap was even larger for #mentalhealth: nearly 4 fewer years free of anxiety and depression for women and nearly 6 for men.
Loneliness, the feeling of being unseen and unheard, weighed more than isolation itself. A healthy diet and exercise softened the effect of isolation but not of #loneliness.
nature.com/articles/s41467-0…
🚨𝗥𝗲𝗽𝗮𝗶𝗿 𝘁𝗵𝗲 𝗹𝗲𝗮𝗸. 𝗜𝗺𝗽𝗿𝗼𝘃𝗲 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀.
🚨𝗥𝗲𝗽𝗮𝗶𝗿 𝘁𝗵𝗲 𝗹𝗲𝗮𝗸. 𝗜𝗺𝗽𝗿𝗼𝘃𝗲 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀.
In TRIC-I-HF, transcatheter tricuspid repair added to medical therapy lowered the hazard of death or heart-failure hospitalization in selected high-risk patients with severe tricuspid regurgitation.
HR: 0.40 through three years.
#PASCAL and #TriClip were the main repair systems used.
The trial evaluated an intervention strategy, not which device is superior.
For structural-heart teams and industry, the focus now includes patient selection, referral pathways, and delivery of treatment.
How should this evidence change your heart-team discussion⁉️
#CardioCircle #CardioX #CardioTwitter #MedTech #StructuralHeart
1
78
Elsayed Balbaa retweeted
Short-form video addiction is linked to rising loneliness and lower life satisfaction.
The quiet toll of endless scrolling.
Elsayed Balbaa retweeted
Meta-analyses of intravascular imaging guidance of PCI show markedly improved outcomes, but only if you use this tool properly — pre-, intra- and post-PCI and with appropriate targets. How do you do it? Our new state-of-the-art review in EHJ takes you through it step by step.



























